Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Novo Nordisk to Double China R&D Headcount

publication date: Sep 14, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Novo Nordisk will expand its Beijing R&D center from 100 employees currently to 200 by 2015. The expansion will create a new Diabetes Research Unit, capable of performing all stages of drug development. At the same time, the company said it expects its China sales to grow at the same 20% annual rate as China healthcare spending, which will take its revenues in China to $1.75 billion by 2015. More details....

Stock Symbol: (NYSE: NVO)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...